|Bid||49.49 x 800|
|Ask||49.51 x 800|
|Day's Range||49.40 - 50.13|
|52 Week Range||29.23 - 58.38|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||52.51|
|Earnings Date||Feb 3, 2020 - Feb 7, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.88|
For growth stocks, Wall Street pros suggest looking at the bigger picture. We mean taking a step back and searching for names capable of rewarding investors for years to come rather than in just the short-term. However, finding these stocks with explosive growth prospects isn’t always easy.That’s where TipRanks.com comes in. Using the platform’s in-depth market data, we were able to zero in on 3 stocks set to see huge gains in the long-run. Having earned enough support from the Street’s analysts in the last three months, all of these names have “Strong Buy” consensus ratings.If that wasn’t captivating enough, analysts note that each of the stocks’ strong growth narratives aren’t fully factored into their share prices, representing a compelling entry point.With this in mind, let’s dive in. Avalara, Inc. (AVLR) Avalara offers customers automated and cloud-based software to make it easier to comply with ever-changing tax laws. With another solid quarterly performance under its belt and an already posted year-to-date gain of 128%, analysts believe AVLR is still undervalued as it’s right on track to deliver massive returns.During its most recent quarter, AVLR was able to report a revenue and earnings beat thanks to substantial customer additions. We’re talking 810 new customers added vs J.P. Morgan analyst Sterling Auty’s estimate of 300. Not to mention the company reached an all-time high net retention rate of 113% and management guided around 25% revenue growth for 2020\. While the results represented a loss, Auty tells investors not to fear as AVLR is just getting started. “We think the stock still has room to move higher driven by these secular growth factors and a valuation that is below many other premium names,” he commented. The five-star analyst adds that its 2020 revenue guidance “likely provides ample opportunity to under promise and over deliver”. As a result, Auty kept his Buy rating and $104 price target. This target conveys his confidence in AVLR’s ability to climb 46% higher over the next twelve months. (To watch Auty’s track record, click here) Like Auty, the rest of the Street has high hopes for AVLR. As 100% of the analysts that have published ratings in the last three months were bullish, AVLR is a ‘Strong Buy’. Additionally, its $98 average price target indicates 37% upside potential. (See Avalara stock analysis on TipRanks) The Trade Desk, Inc. (TTD)This year has seen Trade Desk cement its status as a stand-out growth name, rising 68% year-to-date to be exact. Even though shares have stumbled in the last week, several top analysts cite the online advertising marketplace as a force to be reckoned with.According to its third quarter results, it’s clear why TTD is on Wall Street’s radar. The company surpassed the consensus estimates for both revenue and earnings as well as upped its guidance for the fourth quarter. While this guidance was disappointing for some investors, SunTrust Robinson analyst Youssef Squali argues that TTD is holding up well against the expanding total available market and has been steadily improving margins. Squali also highlights TTD based on its stellar 95%-plus customer retention rate in the quarter as well as its continued efforts to capitalize on international opportunities and a more-data driven approach from agencies and brands. Meanwhile, RBC Capital’s Mark Mahaney believes that TTD is “one of the best positioned stocks to benefit from the shift to streaming” thanks to its rapidly growing connected TV (CTV) segment. The CTV business has grown about 145% year-over-year following many previous quarters of triple digit growth rates. “We estimate CTV to account for close to 20% of TTD’s Revenue in 2020 – and the recent deal with Amazon Fire TV / APS is further evidence of their strong positioning,” he noted. Bearing this in mind, both of the five-star analysts maintain a bullish thesis. Out of the two, Squali sees the largest potential twelve-month gain, with the forecast coming in at 46%. (To watch Squali’s track record, click here) In general, other analysts are on the same page. 6 Buy ratings and 2 Holds assigned in the last three months add up to a ‘Strong Buy’ consensus. The average price target of $247 brings the upside potential to 26%. (See Trade Desk stock analysis on TipRanks) Catalent Inc. (CTLT)Catalent is known for providing integrated services, superior drug delivery technologies and manufacturing solutions to help launch pharmaceuticals, biologics and other consumer health products. With it starting off its fiscal year on a positive note and its shares already up 59% year-to-date, the Street has its eye on CTLT.CTLT’s solid fiscal Q1 2020 performance, which included a 2% EBITDA beat and 11% organic growth, was fueled largely by its Paragon acquisition. In addition, management reaffirmed ibuprofen supply stability for Softgel by pointing out that it has alternative sources to mitigate any possible disruptions in the future. It should also be noted that its strength in the oral drug delivery business stands to drive significant gains for CTLT. All of this played into UBS analyst Daniel Brennan’s conclusion that the company is in it for the long-haul. While acknowledging the tempered stock reaction to these developments, he remains optimistic about CTLT’s prospects. “We see the lack of share price reaction as an opportunity to reiterate our buy rating,” Brennan explained. Along with his Buy rating, the analyst set a $66 price target. Based on this target, shares could surge 33% over the next twelve months. (To watch Brennan’s track record, click here) Similarly, the rest of the Street likes what it’s seeing. With 4 Buy ratings compared to 1 Hold issued in the last three months, CTLT has a ‘Strong Buy’ analyst consensus. On top of this, its $61 average price target implies 23% upside potential. (See Catalent stock analysis on TipRanks)
Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SOMERSET, N.J.-- -- Q1'20 revenue of $664.7 million increased 20% as-reported, or 22% in constant currency, from Q1'19. Adjusted its operating segments to better align internal business unit structure with the "Follow the Molecule" strategy and increase focus on biologics-related technologies, resulting in four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, ...
Cycle Pharmaceuticals Ltd is pleased to announce that it has signed an agreement with Catalent, Inc. , to develop innovative formulations targeting rare disease patients.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paragon Gene Therapy has grown its Maryland employee base to about 750, up from around 400 in April when the biotech announced it would be acquired by New Jersey drug maker Catalent Inc. Paragon, formerly Paragon Bioservices Inc., has been growing rapidly in Greater Baltimore. About 350 of Paragon's employees are based out of a research and development space in the University of Maryland BioPark in Baltimore. The rest are stationed in a new 150,000-square-foot headquarters and manufacturing facility in Anne Arundel County, which opened earlier this year.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2020 ended September 30, 2019, before the market open on Tuesday, November 5, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic...
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Catalent (CTLT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. Catalent reported in-line fourth-quarter results that were highlighted by a 4% organic revenue growth and "stable" EBITDA, Hooker said in a Tuesday downgrade note. The company ended the fiscal year on an encouraging note, with $646 million of development revenue at an estimated mid-to-high-single-digit organic growth rate, he said.
Catalent stock dipped Tuesday after outperforming fiscal fourth-quarter expectations. Catalent earnings rose to 70 cents a share as sales climbed 8% in constant currency to $725.7 million.
Catalent (CTLT) delivered earnings and revenue surprises of 9.38% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Catalent (NYSE: CTLT ) reported fourth-quarter earnings of 70 cents per share, which beat the analyst consensus estimate of 64 cents by 9.37%. This is a 4.48% increase over earnings of 67 cents per share ...